ASCO abstract acceptance provides near-term catalyst visibility (May 29-June 2). However, data are preclinical and the Phase 1/2a trial is early-stage. Monitor for any additional data releases or enrollment updates during the conference. Given the $12M market cap, positive sentiment could drive outsized moves, but clinical risk remains high.
Price Chart
Executive Summary
BioLineRx and partner Hemispherian AS announced that two preclinical abstracts on GLIX1, a first-in-class oral TET2 activator for glioblastoma and other solid tumors, will be presented at the ASCO 2026 Annual Meeting (May 29-June 2). The data highlight GLIX1's novel mechanism of action, strong preclinical antitumor activity in GBM xenograft models, brain penetration (68-85% of plasma levels in mice), and synergistic potential with PARP inhibitors. A Phase 1/2a clinical trial in recurrent GBM is currently enrolling, with updates expected in H2 2026 and full dose-escalation results in 2027.
Key Facts
- Two GLIX1 abstracts accepted at ASCO 2026 (May 29-June 2, Chicago).
- GLIX1 is a first-in-class oral small molecule that reactivates TET2, inducing tumor-selective DNA strand breaks.
- Preclinical data show strong antitumor activity in multiple GBM xenograft models (U87-MG, SNB-19).
- Brain exposure after oral dosing was 68-85% of plasma levels in mice.
- GLIX1 was well-tolerated at highest doses tested: 2000 mg/kg in rats, 1000 mg/kg in dogs.
- Synergistic cytotoxic effects observed with PARP inhibitors across multiple cancer cell lines in vitro.
- Phase 1/2a trial (NCT07464925) in recurrent GBM is enrolling; dose-escalation results expected in 2027.
- BioLineRx has a $12M market cap and is a clinical-stage biopharma with no approved revenue from GLIX1.
Financial Impact
No financial figures disclosed. The filing is a preclinical data announcement with no revenue, guidance, or deal terms.
Risk Factors
- GLIX1 is in early clinical development (Phase 1/2a); no efficacy data in humans yet.
- Preclinical results may not translate to clinical benefit.
- BioLineRx has limited cash runway and may need to raise capital to fund the GLIX1 program.
- Competition in GBM and DNA damage response space is intense.
- Low market cap ($12M) increases volatility risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-002876 |
| Document: zk2635386.htm | 0001178913-26-002876 |
| Document: 0001178913-26-002876-index-headers.html | 0001178913-26-002876 |
| Document: 0001178913-26-002876-index.html | 0001178913-26-002876 |
| Document: 0001178913-26-002876.txt | 0001178913-26-002876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.03 (−0.49%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.03 (+12.50%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.03 (−16.46%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.03 (−21.00%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.03 (+27.50%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.03 (+21.92%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.03 (−32.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers